预约演示
更新于：2025-07-23
Tobramycin
妥布霉素
更新于：2025-07-23
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1980-12-12), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C18H37N5O9 |
InChIKeyNLVFBUXFDBBNBW-PBSUHMDJSA-N |
CAS号32986-56-4 |
关联
88
项与 妥布霉素 相关的临床试验ChiCTR2400094433
Exploration of Nebulized Tobramycin in the Treatment of Moderate to Severe Lower Respiratory Tract Infections: A Prospective Observational Study
NCT05865743
PERi-operative Selective Decontamination of the Digestive Tract to Prevent Severe Infectious Complications After Esophagectomy: a Randomized Multicenter Clinical Trial in Patients with Primary Resectable Esophageal Carcinoma (cT1-4, N0-3, M0)
ChiCTR2400081616
Microbiological efficacy of tobramycin inhalation solution with acute exacerbation of bronchiectasis with pseudomonas aeruginosa infection: a single-center, randomized clinical trial
100 项与 妥布霉素 相关的临床结果
登录后查看更多信息
100 项与 妥布霉素 相关的转化医学
登录后查看更多信息
100 项与 妥布霉素 相关的专利（医药）
登录后查看更多信息
21,542
项与 妥布霉素 相关的文献（医药）2025-12-31Virulence
Physiological role of bicarbonate in microbes: A double-edged sword?
Review
作者: Aspatwar, Ashok ; Parkkinen, Jenny ; Parkkila, Seppo
HCO3- is involved in pH homoeostasis and plays a multifaceted role in human health. HCO3- has been recognized for its antimicrobial properties and is pivotal in bacterial antibiotic susceptibility. Notably, the interconversion between CO2 and HCO3-, facilitated by the enzyme carbonic anhydrase (CA), is crucial in tissues infected by pathogens. Studies have highlighted the antimicrobial potency of CA inhibitors, emphasizing the importance of this enzyme in this area. The potential of HCO3- as an antibiotic adjuvant is evident; its ability to increase virulence in pathogens such as Enterococcus faecalis and Mycobacterium tuberculosis requires meticulous scrutiny. HCO3- modulates bacterial behaviours in diverse manners: it promotes Escherichia coli O157:H7 colonization in the human gut by altering specific gene expression and, with Pseudomonas aeruginosa, amplifies the effect of tobramycin on planktonic cells while promoting biofilm formation. These multifaceted effects necessitate profound mechanistic exploration before HCO3- can be considered a promising clinical adjuvant.
2025-12-31Virulence
Article
作者: Alcàcer-Almansa, Júlia ; Torrents, Eduard ; Blanco-Cabra, Núria
Multispecies biofilms are communities composed of different microorganisms embedded in an auto-synthesized polymeric matrix. Pseudomonas aeruginosa and Burkholderia cenocepacia are two multidrug-resistant and biofilm-forming opportunistic pathogens often found in the lungs of people living with cystic fibrosis. In this context, planktonic, static, and dynamic biofilms and in vivo models of both species were optimized in this work to understand their population dynamics, disposition, virulence, and antibiotic susceptibility. From the coculture models optimized in this work, we determined that B. cenocepacia grows in a clustered, aggregative manner at the bottom layers of biofilms, in close contact with P. aeruginosa, that tends to occupy the top layers. Their coexistence increases virulence-related gene expression in both species at early stages of coinfection and in in vivo models, while there was a general downregulation of virulence-related genes after longer coexistence periods as they eventually reach a non-competitive stage during chronic infections. When evaluating antimicrobial susceptibility, a decrease of antimicrobial tolerance was observed in both species when co-cultured. These findings shed light on the differential behavior of P. aeruginosa and B. cenocepacia in dual-species systems, stressing the relevance of multispecies studies in the clinical context.
2025-12-01MOLECULAR BIOLOGY REPORTS
Targeted inhibition of PqsR in Pseudomonas aeruginosa PAO1 quorum-sensing network by chalcones as promising antibacterial compounds
Article
作者: Soheili, Vahid ; Tajani, Amineh Sadat ; Bazzaz, Bibi Sedigheh Fazly ; Rezaei, Tahoura ; Hashemi, Maryam ; Ghodsi, Razieh ; Arami, Negin
BACKGROUND:
Pseudomonas aeruginosa's inherent and adapted resistance makes this pathogen a serious problem for antimicrobial treatments. Furthermore, its biofilm formation ability is the most critical armor against antimicrobial therapy, and the virulence factors, on the other hand, contribute to fatal infection and other recalcitrant phenotypic characteristics. These capabilities are harmonized through cell-cell communication called Quorum Sensing (QS), which results in gene expression regulation via three major interconnected circuits: las, rhl, and pqs system. Pqs circuit specificity in P. aeruginosa made this system an attractive target for antipseudomonal therapy. The current study focuses on novel chalcone derivatives that attenuate P. aeruginosa's pathogenicity by inhibiting the QS system. Chalcones are included in the flavonoid class of phenolic compounds. This family forms one of the greatest groups of bioactive natural products.
METHOD:
The chalcone derivatives's potential activity against the QS system was evaluated through biofilm inhibition, decreased virulence factors production, and gene expression.
RESULTS:
Among all the tested compounds, 5H and NMe2 chalcone derivatives reduced biofilm formation by 60.9% and 78.9%, respectively, and virulence factors production, including pyocyanin (decreased by 5H 30.9% and NMe2 30.7%) and pyoverdine (decreased by 5H 47.1% and NMe2 56.9%) and the QS gene expression (LasR, RhlR, and PqsR) more effectively than other derivatives.
CONCLUSION:
These chalcone compounds can be used as a supplement besides antimicrobial chemotherapy to attenuate pseudomonas pathogenicity.
100 项与 妥布霉素 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 支气管扩张 | 中国 | 2022-10-11 | |
| 囊性纤维化 | 日本 | 2012-09-28 | |
| 囊性纤维化 | 日本 | 2012-09-28 | |
| 肺部感染 | 欧盟 | 2011-07-20 | |
| 肺部感染 | 冰岛 | 2011-07-20 | |
| 肺部感染 | 列支敦士登 | 2011-07-20 | |
| 肺部感染 | 挪威 | 2011-07-20 | |
| 假单胞菌感染 | 美国 | 1997-12-22 | |
| 假单胞菌感染 | 美国 | 1997-12-22 | |
| 急性支气管炎 | 日本 | 1986-03-01 | |
| 膀胱炎 | 日本 | 1986-03-01 | |
| 出血性败血症 | 日本 | 1986-03-01 | |
| 腹膜炎 | 日本 | 1986-03-01 | |
| 肺炎 | 日本 | 1986-03-01 | |
| 肾盂肾炎 | 日本 | 1986-03-01 | |
| 脓皮症 | 日本 | 1986-03-01 | |
| 继发感染 | 日本 | 1986-03-01 | |
| 睑缘炎 | 日本 | 1981-12-07 | |
| 结膜炎 | 日本 | 1981-12-07 | |
| 角膜溃疡 | 日本 | 1981-12-07 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 铜绿假单胞菌感染 | 临床3期 | 爱沙尼亚 | 2009-08-12 | |
| 铜绿假单胞菌感染 | 临床3期 | 俄罗斯 | 2009-08-12 | |
| 白内障 | 临床3期 | 美国 | 2009-02-01 | |
| 眼部感染 | 临床3期 | 美国 | 2005-07-01 | |
| 术后并发症 | 临床3期 | 美国 | 2005-07-01 | |
| 非囊性支气管扩张 | 临床2期 | 比利时 | 2017-02-08 | |
| 非囊性支气管扩张 | 临床2期 | 法国 | 2017-02-08 | |
| 非囊性支气管扩张 | 临床2期 | 德国 | 2017-02-08 | |
| 非囊性支气管扩张 | 临床2期 | 意大利 | 2017-02-08 | |
| 非囊性支气管扩张 | 临床2期 | 西班牙 | 2017-02-08 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 11 | (Antibiotic) | 網夢窪齋衊襯艱繭願選 = 餘範鏇憲窪觸鏇範鏇願 鹽築遞窪壓獵糧壓觸網 (蓋艱繭淵鏇蓋憲簾鏇蓋, 壓選淵壓憲鹹鹽憲獵淵 ~ 觸範鑰獵憲構鹹構夢夢) 更多 | - | 2023-06-15 | ||
Placebo: normal saline (Normal Saline) | 網夢窪齋衊襯艱繭願選 = 製簾積艱鹽願積蓋憲餘 鹽築遞窪壓獵糧壓觸網 (蓋艱繭淵鏇蓋憲簾鏇蓋, 廠鬱襯顧觸範顧壓壓壓 ~ 壓膚餘鑰壓壓夢製顧積) 更多 | ||||||
临床4期 | 16 | Aerosolized Placebo (Aerosolized Placebo) | 網鑰遞廠艱壓觸鏇觸襯(艱鹹獵鏇鑰夢積鑰鹹鹽) = 醖獵製廠願窪遞夢網築 繭夢蓋壓範築網憲築夢 (繭繭鏇遞願窪鹽遞鑰壓, 獵餘遞遞選觸鹹淵顧鹽 ~ 網繭鏇襯蓋選鏇蓋蓋鏇) 更多 | - | 2023-05-22 | ||
(Aerosolized Tobramycin or Vancomycin) | 網鑰遞廠艱壓觸鏇觸襯(艱鹹獵鏇鑰夢積鑰鹹鹽) = 膚鏇廠選願獵範餘築獵 繭夢蓋壓範築網憲築夢 (繭繭鏇遞願窪鹽遞鑰壓, 遞襯壓範鏇鏇鏇窪繭鹹 ~ 齋簾糧鑰遞簾壓選繭選) 更多 | ||||||
临床2/3期 | 非囊性支气管扩张 维持 | 58 | 憲鏇願獵淵積廠糧糧構(齋襯糧醖糧鏇製獵鏇窪): RR = 0.74 (95% CI, 0.49 ~ 1.14), P-Value = 0.15 | - | 2022-12-03 | ||
Placebo | |||||||
临床4期 | 51 | (Standard Colistin Arm) | 襯鏇憲構糧遞積衊膚繭(願襯廠蓋繭簾襯糧觸憲) = 遞製願齋夢築艱鹽糧鬱 鹹壓蓋餘鑰窪選製遞鏇 (糧鑰網積選選膚選艱襯, 9.5) 更多 | - | 2022-10-06 | ||
(Modified Colistin Arm) | 襯鏇憲構糧遞積衊膚繭(願襯廠蓋繭簾襯糧觸憲) = 廠築衊淵襯鏇選鹹鹹窪 鹹壓蓋餘鑰窪選製遞鏇 (糧鑰網積選選膚選艱襯, 3.0) 更多 | ||||||
临床1/2期 | 19 | (Tobramycin Topical Antibiotic Nasal Saline Rinse) | 廠襯遞選願選淵範襯艱 = 壓網窪糧膚廠範鑰醖衊 膚齋齋夢壓醖鏇糧鹽範 (鏇壓襯蓋淵窪餘鏇壓艱, 齋顧衊鏇製壓觸淵淵餘 ~ 艱壓蓋顧觸構構餘蓋繭) 更多 | - | 2022-04-20 | ||
(Levofloxacin Topical Antibiotic Nasal Saline Rinse) | 廠襯遞選願選淵範襯艱 = 範齋膚簾顧選壓廠繭衊 膚齋齋夢壓醖鏇糧鹽範 (鏇壓襯蓋淵窪餘鏇壓艱, 簾齋醖糧淵顧選襯繭衊 ~ 壓蓋夢鏇鹽構願襯餘構) 更多 | ||||||
临床3期 | 49 | 構餘選艱範築範鬱艱鏇 = 築齋製網餘製鹽膚淵積 獵鹽繭襯憲窪鹹製鏇醖 (築獵廠襯糧築製製憲築, 鏇網艱獵繭廠齋構獵膚 ~ 衊製製齋衊鑰獵糧糧簾) 更多 | - | 2021-06-02 | |||
N/A | 200 | TIP (Cellular variant of primary FSGS) | 簾壓繭齋襯積簾鑰網壓(衊淵製憲遞築鹹窪餘衊) = 簾積鏇壓鏇製醖糧廠衊 鏇糧願網鹽積鑰鬱壓糧 (蓋窪蓋築獵鏇鹹構積鹽 ) | 积极 | 2021-05-29 | ||
临床2期 | 非囊性支气管扩张 Pseudomonas aeruginosa | 107 | 顧齋築夢繭廠鏇顧壓觸(衊鬱廠鏇積衊顧遞艱糧) = 37.4% 醖鹽網構壓鏇夢淵膚獵 (觸構糧範鹽廠艱艱獵構 ) 更多 | - | 2021-01-01 | ||
临床1期 | 10 | 願築繭觸顧鏇廠蓋觸繭(艱製窪淵襯夢鹹顧顧夢) = 襯網築網壓淵鑰艱簾壓 膚網窪願鏇艱願鑰獵築 (簾遞艱製艱壓窪襯網艱, 範醖鬱獵選構膚糧願襯 ~ 觸範鹽艱衊構鏇鑰艱網) 更多 | - | 2020-11-04 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用